BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22128783)

  • 1. Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.
    Rodrigo CM; Cencic R; Roche SP; Pelletier J; Porco JA
    J Med Chem; 2012 Jan; 55(1):558-62. PubMed ID: 22128783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
    Liu T; Nair SJ; Lescarbeau A; Belani J; Peluso S; Conley J; Tillotson B; O'Hearn P; Smith S; Slocum K; West K; Helble J; Douglas M; Bahadoor A; Ali J; McGovern K; Fritz C; Palombella VJ; Wylie A; Castro AC; Tremblay MR
    J Med Chem; 2012 Oct; 55(20):8859-78. PubMed ID: 23025805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK properties.
    Nilewski C; Michels TD; Packard GK; Xiang AX; Sprengeler PA; Eam B; Fish S; Thompson PA; Wegerski CJ; Nevarez A; Clarine J; Sperry S; Ernst JT; Reich SH
    Bioorg Med Chem Lett; 2021 Sep; 47():128111. PubMed ID: 34353608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
    Mahboobi S; Sellmer A; Höcher H; Garhammer C; Pongratz H; Maier T; Ciossek T; Beckers T
    J Med Chem; 2007 Sep; 50(18):4405-18. PubMed ID: 17691763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.
    Thaler F; Varasi M; Colombo A; Boggio R; Munari D; Regalia N; Rozio MG; Reali V; Resconi AE; Mai A; Gagliardi S; Dondio G; Minucci S; Mercurio C
    ChemMedChem; 2010 Aug; 5(8):1359-72. PubMed ID: 20572281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simplified silvestrol analogues with potent cytotoxic activity.
    Hawkins BC; Lindqvist LM; Nhu D; Sharp PP; Segal D; Powell AK; Campbell M; Ryan E; Chambers JM; White JM; Rizzacasa MA; Lessene G; Huang DC; Burns CJ
    ChemMedChem; 2014 Jul; 9(7):1556-66. PubMed ID: 24677741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
    Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model.
    Bordeleau ME; Robert F; Gerard B; Lindqvist L; Chen SM; Wendel HG; Brem B; Greger H; Lowe SW; Porco JA; Pelletier J
    J Clin Invest; 2008 Jul; 118(7):2651-60. PubMed ID: 18551192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and screening of N-alkyl hydroxamates for inhibition of cancer cell proliferation.
    Stanger KJ; Sliva D; Jiang J; Krchnák V
    Comb Chem High Throughput Screen; 2006 Nov; 9(9):651-61. PubMed ID: 17100571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIF-1α inhibitors: synthesis and biological evaluation of novel moracin O and P analogues.
    Xia Y; Jin Y; Kaur N; Choi Y; Lee K
    Eur J Med Chem; 2011 Jun; 46(6):2386-96. PubMed ID: 21481991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors.
    Chu J; Zhang W; Cencic R; Devine WG; Beglov D; Henkel T; Brown LE; Vajda S; Porco JA; Pelletier J
    Cell Chem Biol; 2019 Nov; 26(11):1586-1593.e3. PubMed ID: 31519508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
    Umamaheswari A; Puratchikody A; Hari N
    Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol.
    Müller C; Obermann W; Schulte FW; Lange-Grünweller K; Oestereich L; Elgner F; Glitscher M; Hildt E; Singh K; Wendel HG; Hartmann RK; Ziebuhr J; Grünweller A
    Antiviral Res; 2020 Mar; 175():104706. PubMed ID: 31931103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
    Thuaud F; Bernard Y; Türkeri G; Dirr R; Aubert G; Cresteil T; Baguet A; Tomasetto C; Svitkin Y; Sonenberg N; Nebigil CG; Désaubry L
    J Med Chem; 2009 Aug; 52(16):5176-87. PubMed ID: 19655762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.
    Guandalini L; Cellai C; Laurenzana A; Scapecchi S; Paoletti F; Romanelli MN
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5071-4. PubMed ID: 18723349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.
    Chang LS; Oblinger JL; Burns SS; Huang J; Anderson LW; Hollingshead MG; Shen R; Pan L; Agarwal G; Ren Y; Roberts RD; O'Keefe BR; Kinghorn AD; Collins JM
    Mol Cancer Ther; 2020 Mar; 19(3):731-741. PubMed ID: 31848295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
    He R; Chen Y; Chen Y; Ougolkov AV; Zhang JS; Savoy DN; Billadeau DD; Kozikowski AP
    J Med Chem; 2010 Feb; 53(3):1347-56. PubMed ID: 20055418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
    Shultz M; Fan J; Chen C; Cho YS; Davis N; Bickford S; Buteau K; Cao X; Holmqvist M; Hsu M; Jiang L; Liu G; Lu Q; Patel C; Suresh JR; Selvaraj M; Urban L; Wang P; Yan-Neale Y; Whitehead L; Zhang H; Zhou L; Atadja P
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4909-12. PubMed ID: 21742496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzofused hydroxamic acids: useful fragments for the preparation of histone deacetylase inhibitors. Part 2: 7-fluorobenzothiophenes and benzofurans.
    Marastoni E; Bartoli S; Berettoni M; Cipollone A; Ettorre A; Fincham CI; Mauro S; Paris M; Porcelloni M; Bigioni M; Binaschi M; Nardelli F; Parlani M; Maggi CA; Paoli P; Rossi P; Fattori D
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1603-6. PubMed ID: 25746815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.